替加环素治疗泛耐药鲍曼不动杆菌及肠杆菌科细菌的医院获得性肺炎的疗效  

Efficacy of tigecycline in the treatment of XDRAB and XDRE HAP

作　　者：黄浩[1] 陈湘平[1] 陈凤朱 李程锦[1] 林立伟[1] 

机构地区：[1]福建省立医院北院重症医学科,福建福州350003

出　　处：《临床肺科杂志》2016年第4期690-693,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的评价替加环素治疗泛耐药(extensively drug resistant,XDR)的鲍曼不动杆菌(Acinetobacter baumannii,AB)及肠杆菌科细菌(Enterobacteriaceae,E)医院获得性肺炎(Hospital Acquired Pneumonia,HAP)疗效。方法通过回顾我院两年来使用含替加环素及不含替加环素方案治疗XDRAB及XDRE的HAP患者治疗及预后,对照他们转归是否存在差异。结果组间有效率及死亡率无显著性差异(P>0.05);使用替加环素方案继发铜绿假单胞菌感染显著较多。结论使用替加环素治疗XDRAB及XDRE的HAP无法改善患者有效率及死亡率。Objective To evaluate the efficacy of tigecycline in the treatment of extensively drug resistant （XDR） acinetobaeter baumannii （AB） and Enterobaeteriaceae （E） hospital acquired pneumonia （HAP）. Methods The medical records of patients with XDRAB and XDRE HAP, who had been treated with tigecycline and without tigeeycline, were retrospectively reviewed. The clinical curative effect was compared between the two groups. Results There was no significant difference in total effective rate and mortality between the two groups （ P 〉 0.05 ）. The in- cidence of pseudomonas aeruginosa infection was higher in the study group than in the control group. Conclusion Tigecycline can not increase effective rate and reduce mortality in the treatment of XDRAB and XDRE HAP.

关 键 词：替加环素 XDR 鲍曼不动杆菌 肠杆菌科细菌 肺部感染 疗效 

分 类 号：R446.5[医药卫生—诊断学] R563.1[医药卫生—临床医学]